The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
about
The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations.Dopamine and the Brainstem Locomotor Networks: From Lamprey to HumanExploring Braak's Hypothesis of Parkinson's Disease.The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.Cinnamamide Derivatives for Central and Peripheral Nervous System Disorders--A Review of Structure-Activity Relationships.Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.199 years of Parkinson disease - what have we learned and what is the path to the future?Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.Hyperkinetic disorders and loss of synaptic downscaling.An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease.Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease.Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.Outcome of subthalamic nucleus deep brain stimulation on long-term motor function of patients with advanced Parkinson disease.Oliver Sacks, MD, 1933-2015.Levodopa: 50 years of a revolutionary drug for Parkinson disease.Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.Gene Therapy for Parkinson's Disease, An Update.
P2860
Q30248922-E617739E-A9AE-4738-ACFC-22813CEEECF2Q33729550-4C7A5104-4A8B-44BD-B755-7873D2E2A5C9Q34552244-B130D55D-0C1B-42D8-A5A2-93F00DD5DB9EQ37270927-48FB18F1-2DFB-46C2-A346-0FE85B25F23EQ37668005-DD35F4DB-93B5-44FC-82FA-6C9F806FB1B7Q38530238-BF054BAE-63DB-43CB-A24F-FADFA7149CD8Q38533480-322AD085-5BD5-4218-946B-912CA58FFEF1Q38545359-7B2AA56E-0C90-4930-86CF-A4D60243CAACQ38742951-A906EC48-82D5-4BB7-A17E-750A47C5B90DQ38811387-D7DD2363-7213-4514-94DA-2E63F199BFC1Q38825770-E9D126BD-100D-4E08-9F37-87A954359099Q38834545-7F4D162E-64DF-41C4-9B46-ABEEF68B2CDAQ38847727-640BEC8B-F45F-426E-BEEE-74E68A1134D0Q39012982-B29BAC82-19FE-470D-BE5B-615D6C77AE78Q42615002-CFA01611-196B-4B92-B6ED-C225AB4B2251Q46354756-91109B2E-1954-4144-8160-D26D9E1B9849Q47137220-CD519ECE-2A4A-43B2-97D7-28D907020788Q47773612-C3ED3C4E-DB27-41D8-8EEE-89F320905E12Q48056860-98348902-7616-46F8-A9C0-6706CF4A54F0Q48113961-88E3A17A-4C65-46C7-A098-A9F04AFF1F06Q51442945-EAD18223-125A-4C89-BC6B-3DD957F6F359Q55418920-54A4D9C5-EF9A-4BAD-B036-AA7DB42083E1
P2860
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
@en
type
label
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
@en
prefLabel
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
@en
P2860
P356
P1433
P1476
The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
@en
P2860
P356
10.1002/MDS.26102
P407
P50
P577
2014-12-09T00:00:00Z